Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 149Rituximab 104Peripheral Blood Stem Cell Transplantation 101fludarabine phosphate 100Filgrastim 72Mycophenolic Acid 67Cyclosporine 59Radiotherapy 58Whole-Body Irradiation 57Etoposide 55Tacrolimus 51Busulfan 50Antilymphocyte Serum 43Melphalan 41Methotrexate 37Cytarabine 27Cord Blood Stem Cell Transplantation 26fludarabine 25Bortezomib 24Methylprednisolone 23Carmustine 22sargramostim 21Flow Cytometry 19Dexamethasone 19Lenalidomide 18Granulocyte Colony-Stimulating Factor 18Vincristine 17Prednisone 17Bendamustine Hydrochloride 17aldesleukin 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × Erythromycin × Other hematologic neoplasm × Clear all
NCT02381080 2017-06-26

Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy

Janssen Research & Development, LLC

Phase 1 Completed
26 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡